Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast, Q1'26

By Inderes5/12/2026, 8:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 08:47

Welcome, everyone, to the webcast for Ascelia Pharma AB Q1 report for 2026. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma AB and recent key events, and then we'll head into the portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions. Ascelia Pharma AB. We identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. Our company is based in Malmo, Sweden, and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug that is now under FDA review, with a PDUFA date of July 3, 2026. We will spend the majority of this call talking about Orviglance. ONCORAL is a patented tablet formulation of irinotecan, with encouraging results in Phase 1 and potential to treat a range of solid tumors. Regarding the progress of the first quarter this year, we participated in the European Society for Gastrointestinal and Abdominal Radiology (ESGAR) Conference. There will be an oral presentation about Orviglance by Professor Dominique Geisel from the Charité Hospital in Berlin. Dr. Geisel was an investigator in our Phase 3 study, and Charité is one of the largest hospitals in Europe. During the first quarter, our previously communicated changes in the management team took place as Anton Hansson started as our Chief Financial Officer, and Julie Waras Brogren left Ascelia Pharma; after the close of the quarter in April, we made a directed share issue and raised 20 million Swedish kronor before cost, which extends our cash runway into 2027. We're focused on our two key strategic goals: Orviglance approval and Orviglance partnering. I'm happy to say that we're on track with both of them for the approval. The milestones are the submission of the NDA on September 3rd last year, and in mid-November last year, the FDA set the due date of July 3rd, 2026. This is the date. The due date is the date where the FDA expects to make a decision on the approval of the Orviglance New Drug Application. Our NDA activities, including the interactions with the FDA, are progressing well, and we continue to be on track for the approval. The second objective is to progress Orviglance for commercialization. This is a two-pronged approach. One is to continue to advance launch readiness by ensuring manufacturing and supply chain are ready for launch, as well as working with medical experts, key opinion leaders, payers, and other key stakeholders to ensure the product will have a successful launch whenever that happens in partnership; the other track is to enter into a deal with a partner who will lead and drive the commercialization. I'm proud of the team and the progress we are making on these important milestones, and I'm optimistic for a very strong 2026 for Ascelia Pharma. We will start the portfolio section of our presentation with Orviglance. We are very excited about Orviglance, and here's why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million addressable global market opportunity for Orviglance. Orviglance is a first-in-class product to target this and has Orphan Drug Designation from the FDA. We have commercial scale manufacturing in place, and we have strong data from nine clinical studies, including compelling Phase 3 data. As mentioned, the Orviglance new drug application has been submitted to the FDA, and the due date is coming up in less than two months. Orviglance is an attractive asset that can help patients, and we will work with a partner to drive the commercialization. Let's talk about how Orviglance can help patients. Cancer of the liver is a significant challenge in cancer care. Many different cancer types metastasize to the liver, meaning they start in one organ and spread to the liver. This accounts for roughly 90% of cancer in the liver in the US and Europe. The remaining 10% of cancer of the liver is when the cancer originates in the liver. The liver is often the first organ where the cancer spreads to, and also often the cause of death. That is why cancer in the liver is a major issue in cancer care, and therefore it is important to perform high-quality medical imaging to determine if the cancer has spread to the liver and how the cancer in the liver is responding to therapy or for surgical planning. The best way to do this is with Liver MRI, and to use a Gadolinium-based contrast agent. For most patients, this works well. However, for patients with severe renal disease, they are at risk of a potentially fatal gadolinium-induced side effect known as nephrogenic systemic fibrosis. Regulatory agencies have requested a Black Box Warning on gadolinium products because of this risk. It is exactly these patients that we aim to help with. Orviglance provides high quality imaging, and because it is based on Manganese, there are none of the gadolinium-associated risks. This unmet medical need translates into a global addressable market opportunity of $800 million on an annual basis. The US market is almost half of this, and therefore we have prioritized the US market. Ascelia will work with partners to drive the commercialization of Orviglance. Let's talk a bit more about the key metrics for the US market based on real-world data. There are about 100,000 relevant procedures in the Orviglance target population every year in the US because of their disease and comorbidities. These patients are mostly treated at the major medical centers, and 75% of these imaging procedures are made at the 400 largest Medicare accounts. Based on market research, pricing benchmarks for high-value diagnostic drugs can range from $3,000 to $4,500 per dose. Orviglance is addressing a well-recognized medical need. As mentioned previously, Orviglance is targeting patients with severe renal disease because of the gadolinium associated risks. The medical community is well aware of this, and our market research demonstrates that more than 90% of healthcare professionals are concerned about gadolinium-associated risk, and a number of them have also experienced nephrogenic systemic fibrosis in patients. Orviglance is targeting patients with severe renal impairment, which is the highest-risk population defined by the black box warning. With every gadolinium injection, there is also a deposition of gadolinium in tissue in the body, including in the brain. Every gadolinium injection, there is also a deposition of gadolinium in tissues throughout the body, including in the brain. The consequences of this continue to be evaluated in the scientific community, including long-term effects of the deposition. Another issue is the gadolinium accumulation in our water supply. After the gadolinium contrast injection, the gadolinium is excreted in the urine, which goes into our sewer system, and filtration systems are unable to remove the gadolinium. And as a consequence, gadolinium content in drinking water has increased over the last decades. These are important drivers for the future of MRI. Ascelia Pharma is leading the charge, with Orviglance being based on manganese and under FDA review. If and when approved, it will be the only manganese product on the market. The gadolinium manufacturers recognized the gadolinium challenges. GE HealthCare is developing an injectable manganese agent. They have completed a Phase 1 study and have recently started a Phase 2/3 study. We consider this a positive development with increased focus on manganese agents, and based on what we know, these two products are complementary to each other. The other gadolinium manufacturers have developed gadolinium products with lower doses of gadolinium to reduce the impact. These underlying developments support the need for products such as Orviglance, and we believe the timing for bringing Orviglance to the market is good. We have a clearly stated strategic goal of entering into a partnership with a company that will lead the commercialization of Orviglance. Orviglance represents an attractive commercial opportunity, and we are making good progress in our partnering dialogues. Now we'll transition to the scientific and regulatory section. And Andreas, please go ahead.

Andreas Norlin
08:48 - 15:00

Thank you Magnus. Before I talk about the NDA process, just a few words about the development program of Orviglance. We have an extensive clinical development program, including a total of 286 patients and healthy volunteers across nine clinical studies. Together, these studies have shown a strong, consistent positive benefit-risk profile supporting the intended use in patients in need of a liver MRI and with severe renal impairment. The phase three study, SPARKLE demonstrated that visualization of focal liver lesions measured by the co-primary efficacy variables border delineation and lesion contrast clearly improved with Orviglance compared to unenhanced imaging with a high degree of statistical significance. We could also see that more lesions, especially smaller ones, could be detected in the liver with Orviglance than without. So to summarize, we've built a strong and compelling data package supporting the use of Orviglance in a patient population with a clearly defined and significant unmet medical need. Based on that, we successfully submitted our NDA in September last year, and since then the review has progressed as expected, with a target date for FDA's final decision on July 3rd. Because Orviglance has Orphan Drug Designation for its intended population, we expect to benefit from seven years of regulatory exclusivity following approval. In addition, we filed new patent applications that could extend protection well into the 2040s, further enhancing the long-term commercial opportunity for the product. Overall, we're really pleased with where we are and are very much looking forward to the final stretch leading up to FDA's expected final decision on July 3rd. While our primary focus right now is on securing a successful approval and partnering for Orviglance, we also have Oncoral in our portfolio. That program remains an important asset, and we are looking forward to re-initiation when the timing is right. I'd like to say a few words about that opportunity as well. ONCORAL is a tablet formulation of irinotecan, a well-established intravenous chemotherapeutic agent. A tablet formulation enables a frequent daily, low dose dosing regimen that could offer potential advantages on both efficacy and safety compared to the infrequent high dose intravenous administration that is used today. The opportunity of improving efficacy and safety by administration of daily low doses, also called metronomic dosing, has been demonstrated for irinotecan and other chemotherapeutic agents. In our Phase 1 studies with ONCORAL, we've seen encouraging results that suggest that oral daily administration of irinotecan could offer meaningful benefits to patients. Importantly, the ONCORAL studies have demonstrated an acceptable safety profile and that the uptake of the drug after oral administration is well suited for a metronomic dosing approach. This supports the continued development of ONCORAL as a daily oral formulation of irinotecan. Our plan is to bring ONCORAL into clinical Phase 2 in gastric cancer. Animal data has demonstrated a synergistic effect of irinotecan when combined with Lonsurf, another oral cancer treatment already approved for gastric cancer, which makes this all oral combination very interesting. The plan is to demonstrate clinical proof of concept for the combination of ONCORAL and Lonsurf in gastric cancer. And we start there, and this is today a $3 billion market. Irinotecan is a well-established chemotherapy with recognized anti-tumor effects in many types of solid tumors. Therefore, we see opportunities for developing ONCORAL in other indications where daily dosing could positively impact efficacy and safety outcomes for patients. And we are assessing these opportunities as part of our ongoing strategic planning for ONCORAL. So let's move on to an update of the financials. Anton. Thank you. Andreas. So I will now move on to an update of our financials. And in Q1, our operating results amounted to a loss of 17 million Kroners. And the costs are lower in the quarter compared to Q1 2025 due to the completion of the NDA. At the end of March, we had 34 million in liquid assets. And as Magnus mentioned earlier, after the quarter ended, we successfully completed a directed share issue, raising 20 million SEK before costs in April, and we have now extended our cash runway into 2027. And to summarize, we have significant value creation opportunities ahead. With Orviglance, we are bringing a first-in-class diagnostic drug to market, addressing an $800 million market for patients with high unmet need. And our two key objectives remain timely approval of Orviglance with an optimal label. And here in early September, we submitted the NDA, and the FDA accepted the Orviglance NDA for review in mid-November. And based on a standard ten-month review process, we can expect an approval early July 2026. Our second objective is to progress Orviglance for commercialization for patients in need by entering into a partnering agreement for the launch. These efforts continue to advance. So overall, we continue to progress in Q1 and are well positioned to deliver on our key milestones, and we look forward to continuing our journey with these opportunities for growing Ascelia Pharma AB.

Magnus Corfitzen
15:02 - 15:08

That concludes our quarterly presentation. And now we'd like to open up for questions.

Operator
15:09 - 15:28

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Maria Carlsen Osipova from DAB Carnegie. Please go ahead.

Maria Carlsen Osipova
15:30 - 16:07

Hello. Good morning Ascelia team. I have two short questions. Thank you for the presentation. And of course, obviously all eyes on PDUFA date. And then the report. You state that you're working actively to answer all of the FDA supplementary questions. And in previous calls and reports, you have described this as. And it is a standard back and forth process with the agency. So basically, my question is, has the nature or volume of the questions changed somehow as you're now entering the final stretch? And if you could maybe characterize the types of areas that the agency is now focused on.

Andreas Norlin
16:10 - 16:47

Thank you for that question. I think the simple answer is that we have received questions across the board, and that is, of course, what you expect. FDA is reviewing all sections: efficacy, safety, CMC, nonclinical. And we have received questions. All over. At the end of the review period, you enter the negotiation or discussion about the label. And that is what we expect also here at the end. But everything has been flowing nicely so far.

Maria Carlsen Osipova
16:49 - 17:12

That's good to hear. And another short one. If the FDA approves this on July 3rd, what happens on July 4th or... I think it's Friday. So what happens on July 6th then? Can you walk us through the process? What do the coming 90 days or so look like? What's already in place and what still depends on the potential partner? Maybe.

Magnus Corfitzen
17:14 - 18:08

So you could say, at least as I understand it, we get an approval letter, which will probably hang up. So, have a sort of a copy on the wall to celebrate. I think that's obviously a major transformative milestone. There are some administrative things for setting everything in place, but the next step is getting ready for launch and all the activities that go into that. And as we've said, we want to work with a partner who will drive the commercialization. We have done a lot of work to prepare that. So we have some roadmaps, blueprints, and a lot of market insights. That is going to help the partner get moving fast. So, I think we will work with the partner to make sure everything is lined up for the launch.

Maria Carlsen Osipova
18:13 - 18:16

All right. Thank you. I don't have any more questions. Thank you very much.

Magnus Corfitzen
18:16 - 18:17

Yeah. Thank you Maria.

Operator
18:19 - 18:31

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. The next question comes from Frederick Thaw from Redeye. Please go ahead.

Frederick Thaw
18:33 - 19:10

Hello. Thank you. Thank you. I have a follow-up question for Maria regarding the approval in July. Are there any one-time costs associated with the approval process, or any recurring costs related to the approval that will cease after it? So basically, will the cost development be in a specific way after the approval or will it be quite? Quite stable cost development after the approval. Potential approval?

Magnus Corfitzen
19:13 - 19:46

Yeah. Well, thank you for the question. We're not providing specific cost guidance. I think obviously, responding to questions and requests involves both internal and external experts. And so obviously, it's not for free to be in this process. On the other hand, we also envision other activities after the approval. So I think at this point, we're not expecting major significant changes in our cost structure.

Frederick Thaw
19:49 - 19:52

Got it. That's my question. Thank you very much.

Operator
19:53 - 20:01

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
20:04 - 22:07

There's a question here on whether it's a partnering strategy to complete the negotiations after positive feedback. So I think the overall strategy that we have is to line up for partnering. We have completed the clinical development, finalized the NDA, and are now running the FDA review process. And as we said, we are on track for approval, which I think I'm very proud of the team that can achieve these very challenging milestones. And I think that's a great achievement so far. I think that those achievements also generate value and create a good dynamic in the partnering conversations. The partners are focused on preparing what their commercial team would look like and what is required for the commercial opportunity. And I would say significantly less on the scientific part, because the FDA is basically doing the diligence on that part. So I think that is creating some good dynamics, whether we sign an agreement before the FDA decision or after. It's hard to tell. Obviously from a partner perspective, you have lower risk after the approval. But on the other hand, you could structure the deal in a way where you take out some of the risk on the FDA decision, but I think it could be either or; time will tell where we end up. There are no more questions. So thank you all for joining our Q1 call. And we are, as I mentioned, on track for FDA approval and on our partnering process. So, a very exciting 2026 for Ascelia Pharma AB. And we look forward to updating you on our progress as the year goes on.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…